Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01739673

Enrollment

Registered

2012-12-03

Start date

2011-08-31

Completion date

2014-07-31

Last updated

2018-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Keratitis

Keywords

Infectious Keratitis

Brief summary

This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Interventions

OTHERUltraviolet-A and riboflavin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Subjects must be 18 years of age or older. 2. Ability to provide written informed consent. 3. Likely to complete all study visits. 4. Subjects must have one eye that with a diagnosis of infectious keratitis.

Exclusion criteria

1. A corneal perforation. 2. Descemetocele. 3. Pregnancy or breastfeeding. 4. Active Herpes corneal disease. 5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.

Design outcomes

Primary

Measure	Time frame
Resolution of Signs and Symptoms of Infectious Keratitis	Subjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026